Ferroptosis-centered Drug Response Information
General Information of the Drug (ID: ferrodrug0424)
Name |
DET
|
||||
---|---|---|---|---|---|
Drug Type |
Small molecule
|
Full List of Ferroptosis Target Related to This Drug
Phospholipid hydroperoxide glutathione peroxidase (GPX4)
In total 1 item(s) under this Target | ||||
Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target | [1] | |||
Target for Ferroptosis | Suppressor | |||
Responsed Disease | Melanoma | ICD-11: 2C30 | ||
Pathway Response | Fatty acid metabolism | hsa01212 | ||
Ferroptosis | hsa04216 | |||
Apoptosis | hsa04210 | |||
Cell Process | Cell ferroptosis | |||
Cell proliferation | ||||
In Vitro Model | HaCaT cells | Normal | Homo sapiens | CVCL_0038 |
CCD-966Sk cells | Normal | Homo sapiens | CVCL_U267 | |
A-375 cells | Amelanotic melanoma | Homo sapiens | CVCL_0132 | |
A2058 cells | Amelanotic melanoma | Homo sapiens | CVCL_1059 | |
SK-MEL-2 cells (MEK inhibitor-resistant) cells | Melanoma | Homo sapiens | CVCL_0069 | |
Response regulation | Sesquiterpene lactones DET and DETD-35 significantly reprogram this metabolic adaptation and inhibit GPX4 activity to disturb glutathione metabolism and induce ferroptosis. Targeting ferroptosis and GPX4 could be a novel approach to cope with drug resistance in melanoma cancers. | |||